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Background: Macrophage migration inhibitory factor (MIF) is important in regulating cell proliferation and
apoptosis in both normal and cancerous cells, and may be important in cancer progression and metastasis. In
human non-small cell lung cancer (NSCLC), the underlying mechanisms responsible for MIF-dependent regulation
of cellular proliferation, and cell death remain poorly appreciated.
Methods: The human H460 lung cancer cell-line was treated with an optimally determined dose of 50 pmol/ml
MIF siRNA, following which cell proliferation, cell cycle and apoptosis were analyzed. Additionally, known pathways
of apoptosis including expression of Annexin-V, enhanced production of caspases-3 and −4 and expression of the
Akt signaling protein were assessed in an attempt to provide insights into the signaling pathways involved in
apoptosis following disruption of MIF expression.
Results: Specific siRNA sequences markedly decreased MIF expression in H460 cells by 2 to 5-fold as compared
with the negative control. Moreover, MIF miRNA dampened not only cellular proliferation, but increased the
frequency of apoptotic cells as assessed by cell-surface Annexin-V expression. Entry of cells into apoptosis was
partly dependent on enhanced production of caspases −3 and −4 while not affecting the expression of either
caspase-8 or the Akt signaling pathway.
Conclusions: In a model of NSCLC, knockdown of MIF mRNA expression dampened H460 proliferation by
mechanisms partly dependent on entry of cells into apoptosis and enhanced production of caspase-3 and −4. MIF
expression may thus be important in NSCLC progression. Targeting MIF may have clinical utility in the management
of human lung cancer.
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Lung cancer is the leading cause of cancer-related death in
the world, and accounted for approximately 157,300
deaths in the United States in 2010 [1]. It is estimated that
85-90% of lung cancers are of the non-small-cell lung can-
cer type (NSCLC). With current therapies lacking ad-
equate specificity and efficacy, the median overall survival
rate of patients with metastatic NSCLC remains at* Correspondence: guoyubiao@hotmail.com
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reproduction in any medium, provided the orapproximately 1 year [2,3]. Moreover, It is clear that
chemo-therapy has reached a plateau of activity in the
treatment of NSCLC [4]. Thus, novel treatment strategies
for targeting human lung cancer are urgently warranted.
Macrophage migration inhibitory factor (MIF) is con-
sidered a multifunctional cytokine secreted by a variety
of cells such as macrophages [5], lymphocytes [6], eosin-
ophils [7], epithelial cells [8], and endothelial cells [9],
which importantly, is over-expressed in many different
lung cancers [10-12]. In human lung adenocarcinoma,
MIF modulates tumor cell migration and invasion, in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and membrane lipid raft stabilization; features that are
important in both driving and sustaining tumor cell in-
vasion [13-15].
The functions of MIF are predominantly immunoregu-
latory, serving important roles in inflammation, cell-
mediated and innate immunity [16-19]. In addition, MIF
displays a dominant role in diseases that are character-
ized by pro-inflammatory pathways, such as the severity
of rheumatoid arthritis [20], cardiac dysfunction that is
seen in sepsis [21], Crohn’s disease [22], and many dif-
ferent cancers [23-25].
Since the discovery of MIF almost 50 years ago, more
recent work has identified MIF as a key factor in the de-
velopment and progression of human cancers, and par-
ticularly in the metastatic potential of colorectal and
lung tumors [13,23-29]. Given the known functions of
MIF in pro-inflammatory pathways, and the weight of
evidence associating inflammatory pathways and the de-
velopment of cancer, it comes as no surprise that MIF is
emerging as a key player in the progression and growth
of many tumors [23-29]. It is thought that the ability of
MIF to suppress the anti-inflammatory effects of gluco-
corticoids is central to the inflammatory promoting
functions of MIF, for example in diseases such as acute
respiratory distress syndrome [30,31].
The ability of MIF to suppress anti-inflammatory path-
ways is highly relevant to the growing appreciation of
chronic inflammatory pathways promoting tumor growth
and metastatic development. In host immune defense, in-
flammatory cytokines and other inflammatory mediators
assist in the clearance of infection, eradication of tumors
and in the repair or maintenance of intact tissues and or-
gans. However, the inflammatory milieu, and particularly
in chronic inflammation, provides an environment that as-
sists tumor development and metastasis. The biological
activities of MIF are thought to contribute to these pro-
cesses by inhibiting the regulatory functions of p53 and
thus blocking apoptosis (programmed cell death). It is
thought that this is achieved by certain tumors sustaining
the activation of the ERK signaling pathway via the func-
tional activation of MIF. Such conditions not only attenu-
ate cell death, they also promote tumor cell invasion and
induce the expression of COX-2 and PGE-2 which collect-
ively induce tumor cell growth, tumor cell survival and
metastasis. These are conditions that favor de novo angio-
genesis, thus providing a blood supply to metastatic
tumors [16,32-34].
In the specific setting of non-small cell lung cancer
(NSCLC), monocyte-derived macrophage secretion of
MIF is augmented by NSCLC cells, and secretion of MIF
may contribute to local angiogenic activity and tumor me-
tastasis in cell culture models and mouse models of tumor
development [11,35-37]. A major breakthrough in ourunderstanding of the role of MIF in tumor metastasis in
NSCLC was the identification of CD74 (the invariant
chain of the HLA class II peptide) as the cell surface re-
ceptor for binding MIF [10,38]. Although very little is
known of the relevance of CD74 in many lung cancers,
the expression of CD74 in gastric carcinoma has been as-
sociated with a poor prognosis [39,40]. More recently, as-
sociation of CD74 and MIF co-expression in lung cancers
[10], and the identification of MIF by label-free proteomic
approaches as one of many promising biomarkers in
NSCLC [41], provides additional evidence of the import-
ance of MIF in lung cancer development and progression.
Thus, in the current study, we set out to employ H460
cells as a relevant model system to explore the func-
tional role of MIF in NSCLC. Further, we wished to
assess the molecular mechanisms responsible for the
anti-tumor effects of functionally dampening MIF ex-
pression using specific siRNA sequences. We found that
MIF siRNA transfection inhibited both the proliferation
and induced the apoptosis of H460 cells through mecha-
nisms that were dependent on enhanced production of
caspase-3 and caspase–4, sustained expression of the
Akt/protein kinase B (phosphoinositide 3-kinase, PI3K)
signaling pathway, proliferation arrest and promotion of
an apoptotic mode of programmed cell death.
Materials and methods
Cell culture maintenance and transfection
The human non-small cell lung cancer cell-lines H460
and A549, were both obtained from the Cell Bank of the
Animal Experiment Center, North School Region, Sun
Yat Sen University, Peoples Republic of China. H460
cells were cultured in RPMI-1640 medium (GIBCO,
USA) and A549 cells were cultured in DMEM medium
(GIBCO, USA) where both cultures were supplemented
with 10% newborn calf serum. Both cell-lines were
maintained in a fully humidified incubator at 37°C and
an atmosphere of 5% CO2 in air.
For transfection experiments, two independent siRNA
species were designed to target knockdown of functional
MIF expression and were obtained from Invitrogen (San






The negative control siRNA was also obtained from
Invitrogen, and had the following sequence:
Sense 50-GCGCGCUUUGUAGGAUUCGdTdT −30,
Antisense 50 -CGAAUCCUACAAAGCGCGCdTdT −3.
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seeded into 6-well culture plates, 1.5 × 105 cells per well.
When the confluence of the cells approximated 30-40%
of the available surface area of the culture wells, the cells
were transfected with 50 pmol/ml siRNA (a dose that
was found to be optimal in dose-dependent experi-
ments), using lipofectamine 2000 reagent (Invitrogen,
USA) following the manufacture’s protocol. Cells
transfected with the negative control siRNA were used
to control for the specificity of the miRNA MIF knock-
down studies. The transfection efficiency was monitored
by observation of the frequency of immunofluorescent
positive cells by microscopic examination.
Determination of cell proliferation by MTT assay
Approximately 5 × 103 cells per well were seeded into 96-
well plates and transfected with MIF siRNA or negative
control siRNA, both at a dose of 50 pmol/ml using
lipofectamine 2000 reagent (Invitrogen, USA) following
the manufacture’s protocol. At the indicated time points
of 24 h, 48 h and 72 h post-transfection, the extent of cel-
lular proliferation was measured by MTT assay. This was
done by adding MTT reagent (20 μl) to each well and in-
cubating the plates for an additional 4 h at 37°C. At the
conclusion of the assay, the medium was aspirated, and di-
methyl sulfoxide (150 μl) was added to each well to dis-
solve the formazan product following metabolism of the
MTT reagent. Absorbance values of the formazan product
were measured at a wavelength of 490 nm (A490). Each ex-
periment was repeated at least three times.
Plate cloning assay
A plate-cloning assay was also carried out 24 h after the
transfection of MIF siRNA, In this assay, H460 cells
were collected, trypsinized, and plated into 6-well plates
of 200 cells per well. Cells were cultured in complete
medium (2 ml/well) continuously for 10 days, following
which they were fixed, stained, and observed for the for-
mation of visible cultured cell clones by light micros-
copy. Aggregation of ≥50 cells was considered as a
clone. The percentage of clone formation was calculated
according to the following equation:
Percentage of clone formation
¼ clone number=plated cell numberð Þ  100%
Flow cytometric determination of H460 Apoptosis
The H460 cell-line was seeded at a density of 1.5 × 105
cells/well into 6-well culture plates under conditions de-
scribed above. Cells were treated with either MIF siRNA
or NC siRNA (for the control group) for a period of
48 h of continuous culture in the presence of these
siRNA species. At the conclusion of the assay, cells wereharvested by trypsinization, washed three times in PBS
and resuspended in 0.5 ml PBS. Immediately after resus-
pension of the cells, propidium iodide (PI) and a FITC-
conjugated monoclonal antibody specific for Annexin V
(KaiGi Technology, Guangzhou, China) were incubated
with the cells at 4°C for a period of 30 minutes. Cell
apoptosis was measured using Flow cytometry (Becton
Dickinson Biosciences, Inc., NJ, USA).
Western immunoblotting
Treated H460 cells were lysed in a lysis buffer supple-
mented with a protease inhibitor cocktail (Tissue or Cell
Total Protein Extraction Kit, Shanghai, China). After
10 min incubation on ice, the cell suspension was
centrifuged at 12000 g for 20 min at 4°C. Soluble protein
fractions were then analyzed by Western immunoblotting
performed as follows: First, protein samples were resolved
on 12-15% SDS-PAGE gels. The protein bands were trans-
ferred onto PVDF membranes (Millipore, USA) which
were then blocked overnight in TBS-Tween 20 (TBST)
buffer containing 5% w/v skimmed milk proteins. The
membranes were washed three times with TBST for
10 min each. Second, the membranes were incubated with
an appropriate dilution of a specific primary antibody
targeted against MIF (Abcam, USA), caspases-3, -4 and −8
and AKT (all obtained from Cell Signaling Technology,
USA) with gentle shaking overnight at 4°C. Thirdly, the
membranes were washed thoroughly with TBST and incu-
bated with a HRP-conjugated secondary antibody (Cell
Signaling Technology, USA) for 1 h at room temperature.
Finally, after the membranes were washed with TBST, the
resolved and transferred protein signals were detected by
enhanced chemiluminescence (ECL). The stained bands
were scanned and the relative optical densities measured
for semi-quantitation of the relative expression levels of
each ECL detected protein band.
Statistical analysis
The results were expressed as the arithmetic mean ± one
standard deviation (SD) about the mean. All data were
the product of at least three independent experiments.
The data were analyzed by one-way analysis of variance
(ANOVA) using SPSS 16.0 statistical analysis software
(SPSS Inc, Chicago, IL). An alpha value of P < 0.05 was
considered statistically significant.
Results
MIF is expressed in H460 and A549 cells and siRNA-mediated
MIF knockdown in H460 cells
Prior studies have reported that MIF is over-expressed
in human lung adenocarcinomas [12,13,29]. We evalu-
ated the expression of MIF in H460 and A549 cells, and
found that the expression of MIF was highest in H460
cells (Figure 1). In pilot experiments, we found that a
Figure 1 Expression of MIF protein by Western immunoblot
analysis in H460 and A549 cells. A549 cells showed a weaker
signal for MIF expression as compared with H460 cells normalized to
expression of β-actin. For this reason, we selected the H460 cell-line
as a model of human non-small cell lung cancer in all subsequent
experiments.
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optimal for disrupted expression of MIF (see below).
The transfection efficiency was monitored by immuno-
fluorescence observation and we found that the transfec-
tion efficiency was more than 70% (Figure 2).
In addition, we found that at siRNA concentrations
greater than 50 pmol/ml, the extent of cell death in-
creased dose-dependently with increasing siRNA con-
centrations. Therefore, we selected a dose of 50 pmol/ml
for optimal transfection of H460 cells with siRNA for all
the following experiments.Figure 2 Dose-dependent detection of siRNA transfection efficacy by
were assessed: A: 30 pmol/ml. B: 50 pmol/ml. C: 70 pmol/ml. D: 100 pmol/
cells transfected, we selected a dose of 50 pmol/ml in subsequent experimAfter incubating the cells for 48 h with the MIF siRNA
species, we determined the relative expression of MIF
knockdown by Western immunoblotting (Figure 3). We
found that the expression of MIF protein was signifi-
cantly reduced in the cells transfected with MIF siRNAs
as compared those cells treated with the NC siRNA.
These observations suggested that MIF siRNAs could
dampen the functional expression of MIF in H460 cells
very efficiently (Figure 3).
Determination of the effects of MIF siRNA on H460
cellular proliferation
Using the MTT metabolic and viability assay, the cellu-
lar proliferation and viability of treated H460 was deter-
mined (Figure 4A). We found that in H460 cells treated
with MIF siRNA displayed significantly reduced prolifer-
ation as compared with cells treated with the NC siRNA
control sequence (p <0.05). In addition, the plate cloning
assay indicated that MIF siRNA inhibited the prolifera-
tion of H460 cells (Figure 4B) which was concordant
with the data obtained by MTT assay.
We also assessed the cell cycle dynamics (Figure 5) of
H460 cells treated with the NC siRNA control (A), and
following treatment with either MIF siRNA1 (B), or MIF
siRNA2 (C). In these cell cycle analyses, we could notimmunofluorescence observation. The following doses of siRNA
ml. By visual inspection of the fluorescence intensity and frequency of
ents.
Figure 3 siRNA-mediated knockdown of MIF expression in
H460 cells detected by Western blot. In MIF siRNA-transfected
H460 cells (A), we observed a an approximately two (siRNA 1) to five
(siRNA2) fold weaker signal of MIF protein expression as compared
with the negative control (NC) group normalized to the expression
of β-actin (B).
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compartments wherein the G0/G1 peaks, S-phase and
G2/M phases of the cell cycle appeared quite similar
(Figure 5). Nonetheless, collectively, these data suggest
an important functional role for MIF in lung tumor cell
proliferation.
Knockdown of functional MIF expression promotes
apoptosis
Consistent with the observations indicating apoptotic
modes of cell death in H460 cells treated with MIFFigure 4 Effect of MIF siRNA on the proliferation of H460 cells. (A); M
their proliferation. Each point in the curve represents the arithmetic mean
in triplicate. (B); Plate cloning assay indicated that MIF siRNA inhibited the
obtained from the plate cloning experiments. Data were expressed as arith
*: P < 0.05 as compared with the NC Group. NS: Negative control group.siRNA (Figure 5), we next pursued multi-parameter flow
cytometric analysis of siRNA transfected H460 cells to
obtain more sensitive and quantitative details of a pos-
sible apoptotic mode of cell death (Figure 6A and B).
Following 48 h of culture of MIF siRNA transfected
H460 cells, flow cytometry was used to quantify the ex-
pression of Annexin-V in the absence of PI staining fol-
lowing MIF siRNA treatment (Figure 6A), a condition
which indicated apoptosis. We found that in cells treated
with both MIF siRNA1 and MIF siRNA2, displayed sig-
nificantly higher levels of Annexin-V staining (18.09 ±
0.41% and 23.38 ± 2.67% respectively) as compared their
negative control siRNA treated counterparts (5.87 ±
1.05%, p < 0.05, Figure 6A and 6B). These observations
collectively suggested that MIF may serve important
regulatory roles in apoptosis.
Pathway analysis by western immunoblotting
In an attempt to elucidate the putative mechanisms re-
sponsible for the possible anti-tumor effect of MIF
siRNA, we assessed the relative expression levels of pro-
teins thought to be associated with apoptosis and cellu-
lar proliferation. We found that the expression of the
cleaved band (i.e. caspase-3 and −4) of pro-caspase-3
and −4 were significantly higher in the MIF siRNATT assay showed that treatment of H460 cells with MIF siRNA inhibited
OD values ± SD from representative experiments that were performed
proliferation of H460 cells. Image (C); Quantification of the data
metic mean ± SD, Indicated levels of statistical significance were;
Figure 5 Effect of MIF siRNA on the cell cycle of H460 cells. In propidium iodide stained cells, the cell cycle phases were determined in H460
cells by flow cytometry. The data is described for the cell cycle of H460 cells in the NC group (A), following treatment with MIF siRNA1 (B), and
after treatment with MIF siRNA2 (C).
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caspase-8 (Figure 7A) and Akt in H460 cells remained
unaltered (Figure 7B) irrespective of the siRNA treat-
ment. Collectively, these observations suggest that MIF
siRNA not only blocks cell proliferation of H460 cells,Figure 6 Flow cytometric determination of the effect of MIF siRNA on
three groups: A: cells transfected with NC siRNA, (B) and (C); cells transfecte
treatment, the cells were harvested for quantitation of apoptosis by determ
description of the observed frequency of cells undergoing apoptosis which
MIF siRNA2 (23.38 ± 2.67%) treated groups than in the negative control (NCbut also promotes an apoptotic mode of programmed
cell death that may be dependent, at least in part, on en-
hanced cleavage of pro-caspases-3 and −4 to their ma-
ture functional procaspase counterparts (i.e. caspase-3
and −4) (Figure 7A).Apoptosis of H460 cells. (A); Cultured H460 cells were divided into
d with MIF siRNA (siRNA1 or siRNA2 respectively). After a 48 h
ining changes in the cell surface expression of Annexin-V. (B) shows a
were found to be much higher in the MIF siRNA1 (18.09 ± 0.41%) and
) treated group (5.87 ± 1.05 and p < 0.05) of H460 cells respectively.
Figure 7 Effects of MIF siRNA on cellular expression of caspase-3, caspase-4, caspase-8 and Akt in H460 cells. To determine the
expression of caspase-3, caspase-4, caspase-8 (A) and Akt (B) in differentially siRNA-treated H460 cells, cultures were harvested after a 48 h
treatment, and protein expression patterns assessed by Western immunoblotting analysis and ECL with an appropriate dilution of specific primary
antibodies. Beta-actin was used as loading control for all proteins studied.
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Several reports in the literature have indicates the critical
role of MIF as a regulator of innate and adaptive immunity,
inflammation and tumor progression [16,42]. Increased
expression of MIF has been reported in hepatocellular car-
cinoma, prostate carcinoma, lung adenocarcinoma, neuro-
blastoma and colorectal cancers [13,24,25,27,29]. High
expression of MIF in lung cancer patients predicts a worse
prognosis for disease free and overall survival [11,43]. It
has been shown that CD74 was the cell surface receptor
for MIF [10,38], and that MIF promotes sustained ERK/
MAPK activation through occupation of the cell surface
CD74 receptor [44,45].
A number of reports have shown that MIF is capable
of blocking p53-dependent apoptosis [46], and can acti-
vate the PI3K/Akt pathway [47,48], as well as promoting
endothelial cell proliferation and differentiation [49-51].
These findings confirm that MIF plays an important role
in the development and promotion of human malignan-
cies. Since many of the mechanisms responsible for the
multifactorial functions of MIF have still to be identified,
we have provided important new information with re-
gard to the role of MIF in regulating tumor cell prolifer-
ation and programmed cell death by caspase-3 and
caspase-4 dependent pathways.
In our study, knockdown of the functional expression of
MIF markedly decreased H460 cell proliferation and in-
duced apoptosis as seen by augmented expression of
Annexin-V following treatment of H40 cells by MIF
siRNA. Additionally, caspases plays an essential role in cell
apoptosis and indeed most cell-inducing stimuli direct
apoptosis through the activation of a specific sequence of
caspase proteins. Caspases are cysteine proteases, and
functionally related to interleukin-1β converting enzyme
(ICE). Activation of ICE-like proteases by stimuli that trig-
ger apoptosis, act on substrates such as poly(ADP-ribose)
polymerase or PARP, and activate other enzymes such as
endonucleases and transglutaminase, which leads to energy
(ATP and ADP) depletion, ER stress, protease activation,cytoskeletal disorganization, and apoptotic body formation.
Thus, the enhanced cleavage of pro-caspase-3 and pro-
caspase-4 to their biologically active pro-caspase counter-
parts that we found in this study following treatment of
H40 cells with MIF siRNA, is a key feature of the highly
regulated cell death process of apoptosis.
Significant evidence has accumulated suggesting that
the endoplasmic reticulum (ER) plays a crucial role in the
execution of apoptosis [52,53]. For example, caspase-12,
has been shown to induce apoptosis in response to ER
stress [54] and in humans, the ER-mediated killing role of
caspase-12 has been found to be substituted by caspase-4
[54,55]. Moreover, caspase-4 has been found to be a spe-
cific mediator of ER stress and may play an important role
in the ER-stress pathway [55,56].
By contrast, caspase 3 is downstream effector protein,
and it takes part in the functionally crucial decision and
execution phases of the apoptosis process [57]. Caspase-
8 is generally considered to be an initiator caspase due
to its ability to be associated with the cell surface death
receptor that transduces apoptosis via the structural sig-
naling complexes FADD/MORT1 and RAIDD/TRADD.
Indeed, the amino terminal of the death effector domain
(DED) of FADD/MORT1 is required for death induc-
tion and interacts structurally with the prodomain of
caspase-8, which recruits the FLICE/MACH death ef-
fector proteins that implement apoptosis.
In our study, the expression of the cleaved band of both
caspase-3 and caspase-4 are significantly increased in the
MIF siRNA groups. This data not only suggests that
siRNA-mediated knockdown of MIF can promote cellular
apoptosis in human lung H460 cells, but does so in
caspase-3 and caspase-4 dependent mechanism. It is
tempting to speculate that the ER-stress pathway is in-
volved in this process following pro-caspase cleavage and
activation, yet this will need to await formal demonstration
in our model system described in the current work.
In conclusion, we have shown that MIF increases the
proliferation and blocks, at least in part, the apoptosis of
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ways under conditions where the functional expression
or activity of both caspase-8 and the Akt signaling path-
way remains unaltered. We propose that dampening of
the functional expression of MIF could reasonably be
exploited as a clinically useful strategy in the manage-
ment of many tumors including lung cancer.
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